Enhancing HER2 Evaluation: Correlation between APIS Breast Cancer Subtyping Kit and IHC/ISH for Accurate HER2 Quantification

被引：0
|
作者：
Gasior, A. [1 ]
Gorniak, J. [1 ]
Rollinson, S. [1 ]
Gough, L. [1 ]
Wegscheider, A. [2 ]
Niendorf, A. [2 ]
机构：
[1] APIS Assay Technol, Manchester, Lancs, England
[2] MVZ Prof Dr Med A Niendorf Pathol Hamburg West Gm, Hamburg, Germany
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2023年 / 25卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
ST047
引用
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [21] Precision HER2: a comprehensive AI system for accurate and consistent evaluation of HER2 expression in invasive breast Cancer
    Xiong, Zhongtang
    Liu, Kai
    Liu, Shaoyan
    Feng, Jiahao
    Wang, Jin
    Feng, Zewen
    Lai, Boan
    Zhang, Qingxin
    Jiang, Qingping
    Zhang, Wei
    BMC CANCER, 2024, 24 (01)
  • [22] Evaluation of HER2 IHC Staining Using the Ventana Image Analysis System, Correlation with HER2 FISH Amplification
    Dennis, J. A.
    Parsa, R.
    Chau, D.
    Peng, Y.
    Sahoo, S.
    Fang, Y. V.
    Sarode, V. R.
    MODERN PATHOLOGY, 2013, 26 : 36A - 36A
  • [23] Evaluation of HER2 IHC and FISH in breast cancer with digital pathology platform
    Micsik, T.
    Krenacs, T.
    Ficsor, L.
    Molnar, B.
    VIRCHOWS ARCHIV, 2009, 455 : 98 - 98
  • [24] Reproducibility of equivocal HER2 in situ hybridisation (ISH) results in invasive breast cancer, and correlation with HER2 mRNA expression as determined by Mammatyper®
    Riggi, J. A. M.
    Baez-Navarro, X.
    Zylberberg, D.
    van der Made, A.
    Dubois, D.
    Vanderveken, J.
    Benhaddi, N.
    Duhoux, F. P.
    Vernaeve, H.
    Vassilieff, M.
    Berliere, M.
    Galant, C.
    van Deurzen, C. H. M.
    van Bockstal, M. R.
    BREAST, 2025, 80
  • [25] Evaluation of HER2 IHC Staining Using the Ventana Image Analysis System, Correlation with HER2 FISH Amplification
    Dennis, J. A.
    Parsa, R.
    Chau, D.
    Peng, Y.
    Sahoo, S.
    Fang, Y. V.
    Sarode, V. R.
    LABORATORY INVESTIGATION, 2013, 93 : 36A - 36A
  • [26] HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC)
    Nuciforo, Paolo
    Aura, Claudia
    Thyparambil, Sheeno P.
    Vilaro, Marta
    Garrido-Castro, Ana C.
    Peg, Vicente
    Jimenez, Jose
    Hoos, William Arthur
    Burrows, Jon
    Hembrough, Todd A.
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Scaltriti, Maurizio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
    Yuefeng Wang
    Julia Y. S. Tsang
    Yongmei Cui
    Ji Cui
    Ying Lin
    Songli Zhao
    Patrick T. W. Law
    Sai Yin Cheung
    Enders K. O. Ng
    Gary M. K. Tse
    Zunfu Ke
    Scientific Reports, 7
  • [28] Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
    Wang, Yuefeng
    Tsang, Julia Y. S.
    Cui, Yongmei
    Cui, Ji
    Lin, Ying
    Zhao, Songli
    Law, Patrick T. W.
    Cheung, Sai Yin
    Ng, Enders K. O.
    Tse, Gary M. K.
    Ke, Zunfu
    SCIENTIFIC REPORTS, 2017, 7
  • [29] Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer
    Johnston, Laura E.
    Randall, Jamie
    Chouraichi, Safae
    Luu, Mary
    Hunt, Allison L.
    Mauro, Lauren
    Mueller, Claudius
    Davis, Justin B.
    Petricoin, Emanuel F.
    Conrads, Thomas P.
    Cannon, Timothy L.
    Huynh, Jasmine
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [30] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
12345